Overview
Status
Active
Registry date
2017-02-21
Share capital
5,000.00 PLN
Registered address
ul. Augusta Cieszkowskiego 1/3/125, 01-636 Warszawa, Poland
Financials
Revenue history
Filing timeliness
No financial statement for 2025 – the filing deadline has passed. 5 of 6 financial statements were filed late (the longest delay 368 days for 2019).
- 2025not filed
- 202409/09/2025
- 202329/07/2024
- 202225/07/2023
- 202123/09/2022
- 202003/08/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Industry
Authorized Representatives
Mariusz Andrzej Głowacki – President of the Management Board
Manner of representation
In the case of a multi-member management board, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Mariusz Andrzej Głowackiage 55 | 50 | $675.31 | 50% |
Karol Pawlakage 52 | 50 | $675.31 | 50% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2021-03-12.
No bank accounts reported to the VAT Taxpayer Register.
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Dec 31, 2019 | Aid for research and development projects: industrial research | $673.3K$673,316 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Dec 31, 2019 | Aid for research and development projects: experimental development | $255.7K$255,736 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Nov 22, 2019 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $92,724$92,724 | Dyrektor Narodowego Centrum Badań i Rozwoju |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i AdministracjiResearch institute | $355,967,543.57 | cskmswia.pl | ||
| FamicordtxS.A. | $1,365,068.41 | famicordtx.com | ||
| Medicofarma BiotechS.A. | $314,882.33 | medicofarmabiotech.pl | ||
| Explorna Therapeuticssp. z o.o. | $304,662.00 | explorna.com | ||
| Frontline BiosciencesS.A. | $219,186.29 | frontlinebiosciences.com | ||
| AI Corelabsp. z o.o. | $128,365.55 | aicorelab.com | ||
| Stenocoatsp. z o.o. | $36,665.21 | stenocoat.com | ||
| Bioselsp. z o.o. | $19,100.32 | selol.pl | ||
| Wavex Energysp. z o.o. | $142.33 | wavexenergy.com | ||
| Nawah Scientific Polandsp. z o.o. | – | nawah-scientific.com |
FAQ
The main business activity of GP Bionics focuses on research and experimental development on biotechnology.
The company was registered in the Polish National Court Register (KRS) on February 21, 2017.
The headquarters is located at: ul. Augusta Cieszkowskiego 1/3, 01-636 Warszawa.
The management board consists of: Mariusz Andrzej Głowacki (President of the Management Board).
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.
Last updated: 2026-04-22